$5190
$4152
The epilepsy drugs market size is projected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is estimated to record a CAGR of 4.1% during 2022–2030. Rising Research & Development (R&D) activities are likely to remain key trends in the market.
Epilepsy Drugs Market Analysis
Rising clinical trials for epilepsy drugs to develop innovative drugs will provide a lucrative opportunity for market growth in the coming years. For example, Mayo Clinic conducted a clinical trial to investigate the effectiveness and safety of "Fenfluramine Hydrochloride Oral Solution (ZX008) as an Adjuvant Therapy for children with Intractable Epilepsy with Myoclonic-Atonic Seizures. Further, rising incidence of epilepsy cases accelerates demand for antiepileptic drugs will drive market growth. For example, companies launching innovative products by the company is an influential factor responsible for accounting for considerable market growth during 2020-2030. Rising Research & Development (R&D) activities are likely to remain key trends in the market.
Epilepsy Drugs Market Overview
According to the WHO report, globally, an estimated 5 million people are diagnosed with epilepsy annually. For records, in high-income countries, there are an estimated 49 per 100000 people diagnosed with epilepsy, and in low-income countries, this figure is as high as 139 per 100000. The World Health Organization (WHO) report further reveals that epilepsy accounts for more than 0.5% of the global burden of disease, with out-of-pocket costs creating a substantial burden on households. Therefore, rising cases of epilepsy will accelerate demand for antiepileptic drugs in the coming decade.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epilepsy Drugs Market: Strategic Insights
Market Size Value in US$ 7,768.50 million in 2022 Market Size Value by US$ 10,705.48 million by 2030 Growth rate CAGR of 4.1% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epilepsy Drugs Market: Strategic Insights
| Market Size Value in | US$ 7,768.50 million in 2022 |
| Market Size Value by | US$ 10,705.48 million by 2030 |
| Growth rate | CAGR of 4.1% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Epilepsy Drugs Market Drivers and Opportunities
Rising Incidence of Epilepsy Cases Accelerate Demand for Antiepileptic Drugs to Favor Market
According to the WHO 2024 published report, around 50 million people globally have epilepsy, making it the most common neurological disease—the rising incidence of epilepsy results in a considerable burden of healthcare costs worldwide. For example, it has been estimated that the 6 million people with active epilepsy cost over US$21.5 billion annually, and despite this, very few European countries have national plans to manage epilepsy disorder. Therefore, demand for antiepileptic drugs is high in demand to prevent seizures. For example, upto 70% of people living with epilepsy could become seizure free with appropiate use of antiseizures medicines as per the WHO report. Furthermore, rising prevalence of epilepsy cases accelerate demand for antiepileptic drugs are the major drivers of global epilepsy drugs market share.
Rising Clinical Trials for Epilepsy Drugs Provide Lucrative Market Opportunity
For example, Équilibre Biopharmaceuticals’s "EQU-001" witness "Phase Transition Success Rate (PTSR)" as the company reported Phase 2 results for anti-epileptic drugs. Additionally, the SANAD clinical trial was design to identofy the most effective and cost-effective treatments for patients with epilepsy. Previosuly "Valproate" was approved to control the seizures and was more efficacious over "Lamotrigine" and was the first drug choice for many patients suffering from generalized and unclassified epilepsies. However, due to adverse effects of valproate during pregnancy the physicians stop prescribing the drug. Further, the Lamotrigine through clinical trials was clinially proven better than valproate with cost effective alternative for patients diagnosed with partial onset seizures. Further, in 2024, the results from the clinical trial SANAD-2 are yet to be announced for new antiepileptic drugs. Therefore, rising clinical trials for development of new antiepileptic drugs is seen to leave a positive impact on the market, as it has an opportunity for innovative drugs.
Epilepsy Drugs Market Report Segmentation Analysis
Key segments that contributed to the derivation of the epilepsy drugs market analysis are type, cause, disorder type, category, and end user.
- Based on treatment, the epilepsy drugs market is segmented as first-generation anti-epileptics, second generation anti-epileptics, third generation anti-epileptics. The second generation anti-epileptics segment held the largest market share in 2022.
- By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2022.
Epilepsy Drugs Market Share Analysis by Geography
The geographic scope of the Epilepsy Drugs market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market. In North America region, the US accounts largest share for epilepsy drugs market. Presence of top manufacturers in the region and their innovative antiepileptic drugs having effective pharmacological activity are the factors contributing to the dominance of the market. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
Epilepsy Drugs Market Report Scope
Epilepsy Drugs Market News and Recent Developments
The Epilepsy Drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Epilepsy Drugs market are listed below:
- Eisai Co., Ltd. announced new product launch "Fycompa" intended for intravenous (IV) infusion. The injection formulation of Fycompa received manufacturing and marketing approval on January 2024 and this was included in the Japan's National Health Insurance (NHI) Drug Price list today. Fycompa is the first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. (Source: Eisai Co., Ltd, Press Release, April 2024)
Epilepsy Drugs Market Report Coverage and Deliverables
The “Epilepsy Drugs Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
- Epilepsy Drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Epilepsy Drugs market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Epilepsy Drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Epilepsy Drugs market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Treatment, Distribution Channel, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The estimated value of epilepsy drugs market accounted US$ 11.9 billion in 2031.
UCB SA, Novartis AG, Pfizer, GSK, Abbott, Sanofi, Sumito Pharma Company, Teva Pharmaceuticals, Catalyst Pharmaceuticals, and Alkem Laboratories are the key players in the epilepsy drugs market.
Rising Research & Development (R&D) activities to remain as a key trend for epilepsy drugs market.
Rising incidence of epilepsy cases accelerate demand for antiepileptic drugs is one of the most influential factors responsible for market growth.
North America region dominated the epilepsy drugs market in 2023.
The CAGR for epilepsy drugs accounted 4.5% during 2023-2031.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Drugs Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Epilepsy Drugs Market - Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. Epilepsy Drugs Market - Global Market Analysis
6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 – 2030
7. Global Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Treatment
7.1 Overview
7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. Global Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. Epilepsy Drugs Market – Revenue and Forecast to 2030 – Geographic Analysis
9.1 North America: Epilepsy Drugs Market
9.1.1 Overview
9.1.2 North America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.1 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.1 Overview
9.1.4.1.2 US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.1 Overview
9.1.4.2.2 Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.1.4.3 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.1 Overview
9.1.4.3.2 Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2 Europe: Epilepsy Drugs Market
9.2.1 Overview
9.2.2 Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.2.5.1 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.3 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.4 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.5 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.2.5.6 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3 Asia Pacific: Epilepsy Drugs Market
9.3.1 Overview
9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.3.5.1 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.1 Overview
9.3.5.1.2 China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.1 Overview
9.3.5.2.2 Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.3 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.1 Overview
9.3.5.3.2 India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.4 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.1 Overview
9.3.5.4.2 Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.5 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.1 Overview
9.3.5.5.2 South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4 Middle East & Africa Epilepsy Drugs Market
9.4.1 Overview
9.4.2 Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.1 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.1 Overview
9.4.4.1.2 South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.1 Overview
9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.3 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.1 Overview
9.4.4.3.2 UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.1 Overview
9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5 South & Central America: Epilepsy Drugs Market
9.5.1 Overview
9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5 South & Central America: Epilepsy Drugs Market Share by Country – 2022 & 2030, (%)
9.5.5.1 Brazil: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.1.1 Overview
9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.2 Argentina: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.2.1 Overview
9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.1 Overview
9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020–2030 (US$ Million)
9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020–2030 (US$ Million)
10. Epilepsy Drugs Market–Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 UCB SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novartis AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Pfizer Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 GSK Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott Laboratories
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Sanofi SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. Epilepsy Drugs Segmentation
Table 2. North America Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 4. US Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 5. US Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 6. Canada Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Mexico Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 9. Mexico Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 10. Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 11. Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 12. Germany Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. France Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 15. France Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 16. UK Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 17. UK Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 24. Asia Pacific Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 25. Asia Pacific Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 26. China Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 27. China Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 28. Japan Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 29. Japan Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 30. India Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 31. India Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 32. Australia Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 33. Australia Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 34. South Korea Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 35. South Korea Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Asia Pacific Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 37. Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 38. Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 39. Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 40. South Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 41. South Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 42. Saudi Arabia Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 43. Saudi Arabia Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 44. UAE Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 45. UAE Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Middle East & Africa Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Middle East & Africa Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 48. South & Central America: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 49. South & Central America: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 50. Brazil: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 51. Brazil: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 52. Argentina: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 53. Argentina: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 54. Rest of South & Central America: Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 55. Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 56. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
Table 57. Recent Organic Growth Strategies in the Epilepsy Drugs Market
Table 58. Glossary of Terms, Epilepsy Drugs Market
List of Figures
Figure 1. Epilepsy Drugs Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. Epilepsy Drugs Market: Key Industry Dynamics
Figure 4. Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 5. Epilepsy Drugs Revenue (US$ Mn), 2022 – 2030
Figure 6. Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 7. First Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Second Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Third Generation Anti-epileptics: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 11. Hospital Pharmacy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Retail Pharmacy Stores: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 15. North America Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 17. US: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Canada: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Mexico: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 21. Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 23. Germany: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. France: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. UK: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Italy: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Spain: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Rest of Europe: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Asia Pacific: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 30. Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 32. China: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Japan: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. India: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 35. Australia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 36. South Korea: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rest of Asia Pacific: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 38. Middle East & Africa: Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
Figure 39. Middle East & Africa Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 40. Middle East & Africa: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 41. South Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 42. Saudi Arabia: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 43. UAE: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 44. Rest of Middle East & Africa: Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 45. South & Central America: Epilepsy Drugs Market, By Key Country – Revenue (2022) (US$ Million)
Figure 46. South & Central America: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 47. South & Central America: Epilepsy Drugs Market Share by Country – 2022 & 2030, (%)
Figure 48. Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 49. Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 50. Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 51. Growth Strategies in the Epilepsy Drugs Market
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Epilepsy Drugs Market
Nov 2023
Infectious Disease Therapeutics Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others),  and Geography
Nov 2023
Clinic Casting and Splinting Products Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product [Casting (Casts, Tapes, Cutters, and Casting Accessories) and Splinting (Splints and Splinting Accessories)], Application (Acute Fractures or Sprains, Tendon and Ligament Injuries, and Others), Material (Plaster of Paris, Fiberglass, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2023
Myopia Treatment Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (High Myopia, Degenerative Myopia, Progressive Myopia), Treatment [Low-Dose Atropine Eye Drops, Ortho-K, Contact Lenses, and Refractive Surgery (LASIK, PRK)], Age Group (Adult Myopia and Childhood Myopia), End User (Hospitals and Clinics, Specialty Clinics, and Refractive Surgery Centers), and Geography
Nov 2023
Epilepsy Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs), Age Group (Adults and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Nov 2023
Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others), Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant), and Geography
Nov 2023
Human Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others), and Geography
Nov 2023
Epilepsy Drugs Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment (First-Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Nov 2023
Specialty Hospitals Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Specialty Type (Pediatric Hospitals, Obstetrics-Gynecology Hospitals, ENT Hospitals, Oncology Hospitals, Rehabilitation Hospitals, Orthopedic Hospitals, Neurology Hospitals, Cardiology Hospitals, IVF Hospitals and Others), Service Type (Outpatient and Inpatient), Hospital Type (Public Hospitals and Private Hospitals), and Geography (North America, Europe, Asia Pacific, and Middle East & Africa)